After FDA authorizes at-home saliva test for Covid-19, startups begin selling test kits.

MedCityNews The FDA gave an emergency use authorization for the first saliva-based Covid-19 test developed by RUCDR Infinite Biologics....
Biotech Stock Review

Biotech Stock Review Adds One Medical (ONEM) $28.50 to Watchlist.

It Ain't Cheap at $3.5 Billion.It's Near Doubled Since March 20th.But Look at the Growth.Look at the Cash.Don't Look at the Bottom...

SEC takes enforcement action against 23 companies for claims relating to COVID-19.

Aint Nothing but a Gangter Party. Like cryptocurrency and cannabis, the coronavirus pandemic may attract fraudsters keen to profit...

Update: Biotech 5 Pack. 5 Biotech Stocks, we Expected to Double in 2020.

No Doubles Yet, But They're Doing Rather Well, Considering Everything. Our Confidence Remains Unwavered. Best Performer up 63%.

Citius Pharma (CTXR) Seeks Expeditious Pathway Into the Clinic, for CoronaVirus Related Acute Respiratory...

Sumbmits pre-IND Into Coronavirus Treatment Acceleration Program (CTAP).   Citius Announces Pre-IND Submission to FDA Under the Coronavirus...

European Hand Sanitizer Market Expected to Reach $9.4 Billion by 2027.

Growing at a CAGR of 38.4% during 2019–2027. The European hand sanitizer market was valued at US$ 641.7 million...

Revive Therapeutics Announces Entry Into Phase III FDA Trial Using Glutathione Boosting Bucillamine.

Revive Therapeutics Announces U.S. FDA Recommendation to Proceed Directly Into A Phase 3 Confirmatory Clinical Trial TORONTO, April...
Super Gonorrhea

Antibiotic-Resistant Super Gonorrhea (CDC).

"We are currently down to one last recommended and effective class of antibiotics, cephalosporins, to treat this common...

Is Overuse of Antibiotics on Farms Worsening the Spread of Antibiotic-Resistant Bacteria? (CBSNews)

Public health officials investigating a drug-resistant salmonella outbreak in 2015 still don't know the exact source after a pork-industry lobbying group on...

Drug Resistance Could Kill 10M People per year by 2050, Experts say (Axios).

Infectious disease experts tell Axios they agree with a dire scenario painted in the UN report posted earlier this week saying that, if nothing...

Latest article

We’re in Tampa for the Kentucky Derby.

GeoVax (GOVX), Sees a Little Volume. Normally, we get a little nervous when one of the companies we...

Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX.

DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26...

Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.

Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!